Chemomab merging into Scipher Medicine to pivot nebokitug into AI-selected RA, abandoning PSC after Phase 2 biomarker-only results

Bull

A positive readout would show statistically meaningful improvement on standard 12-week FDA RA endpoints (e.g., ACR20/50/70 response rates) in the PrismRA-selected patient population, demonstrating that AI-driven patient selection can unlock a signal for nebokitug that broad enrollment would have missed. This would validate both Scipher's Network Medicine platform as a differentiated drug-development tool and nebokitug's CCL24/CCL2-targeting mechanism in RA, potentially supporting a pivotal program and meaningfully de-risking the combined company's valuation.

Bear

The most likely failure mode is that nebokitug fails to demonstrate a clinically meaningful or statistically significant ACR response even in the AI-enriched population, suggesting that CCL24 antagonism is not a relevant mechanism in RA regardless of patient selection. A second failure mode is that the PrismRA biomarker selection itself proves insufficient — patient enrichment works in theory but the selected subgroup remains biologically heterogeneous — undermining the core premise of the Scipher merger and leaving the combined entity without a credible clinical program.